
Opinion|Videos|June 16, 2025
Improving diversity in future clinical trials for mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Enhancing diversity in mHSPC clinical trials requires community outreach, collaboration, and accessible care for underrepresented populations.
Advertisement
Episodes in this series

Improving Clinical Trial Diversity
Key Themes:
- A multistakeholder approach is required (patients, communities, clinicians, payers, industry).
- Community outreach initiatives are essential for building trust.
- A comprehensive approach is needed to address the barriers to participation.
- Bring clinical trial access directly into communities of color.
Key Points for Physicians:
- Support or participate in community outreach programs.
- Address practical barriers to clinical trial participation with patients.
- Consider geographical and logistical factors when referring patients to trials.
- Recognize the importance of building trust through community engagement.
Notable Insights: Creating direct conduits to high-quality care through community-based initiatives represents a practical strategy for improving trial diversity and addressing historical mistrust.
Clinical Significance: Systematic approaches to improving trial diversity are essential for generating evidence applicable to all patient populations and addressing historical health care disparities.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
5











